Epigenetic plasticity and antiandrogen resistance in prostate cancer

When

Mon, Feb 26, 2018 12:00 pmuntilMon, Feb 26, 2018 1:00 pm

Where

Life Sciences Building Auditorium
145 Bevier Road
Piscataway
NJ
08854

Contact

Event Actions

About

David W. Goodrich, Ph.D.
Professor of Oncology
Associate Dean for Postdoctoral Education
Roswell Park Cancer Institute

Evidence will be presented indicating RB1 loss drives transformation of prostate adenocarcinoma to neuroendocrine prostate cancer. This process is mediated by epigenetic reprogramming factors because inhibiting their activity reverses neuroendocrine transformation. I will discuss therapeutic implications and the wider relevance of this mechanism for therapeutic resistance to molecularly targeted therapies.